MRPL49 and retinopathy of prematurity: We previously reported the advantage of anti-Scg3 ML49.3 mAb and EBP2 hAb, which stringently inhibits pathological but not physiological angiogenesis in animal models of retinopathy of prematurity (ROP) [21,23].